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Primary hyperoxalurias (PH) are inborn errors in the metabolism of glyoxylate and oxalate. PH type 1, the most common
form, is an autosomal recessive disorder caused by a deﬁciency of the liver-speciﬁc enzyme alanine, glyoxylate aminotransferase
(AGT) resulting in overproduction and excessive urinary excretion of oxalate. Recurrent urolithiasis and nephrocalcinosis are the
hallmarks of the disease. As glomerular ﬁltration rate decreases due to progressive renal damage, oxalate accumulates leading
to systemic oxalosis. Diagnosis is often delayed and is based on clinical and sonographic ﬁndings, urinary oxalate assessment,
DNA analysis,and, if necessary, direct AGT activity measurement in liver biopsy tissue. Early initiation of conservative treatment,
including high ﬂuid intake, inhibitors of calcium oxalate crystallization, and pyridoxine in responsive cases, can help to maintain
renal function in compliant subjects. In end-stage renal disease patients, the best outcomes have been achieved with combined
liver-kidney transplantation which corrects the enzyme defect.
1.Introduction
Hyperoxaluria may be either inherited or acquired. The
primary hyperoxalurias(PH)areinborn errorofmetabolism
resulting in increased endogenous production of oxalate
leading to excessive urinary oxalate excretion. To date, three
distinct hereditary enzymatic deﬁciencies have been linked
to PH, namely, PH type 1 (PH1), type 2 (PH2), and type
3 (PH3), and there is evidence to speculate that further
causes are yet to be identiﬁed. Due to marked hyperoxaluria,
recurrent urolithiasis and progressive nephrocalcinosis are
the principal manifestations of PH. As a result of kidney
injury, glomerular ﬁltration rate (GFR) declines leading to
chronic kidney disease, and ultimately to end-stage renal
disease (ESRD) and systemic involvement in PH1, the most
severe type of PH. Despite recent improvement in disease
spectrum knowledge, diagnostic procedure, and treatment
strategies, PH1 still represents a challenging issue for both
adult and pediatric nephrologists worldwide.
2.Physiopathology
Primary hyperoxalurias are inborn errors in the metabolism
of glyoxylate and oxalate (Figure 1). They are characterized
by an excessive production of oxalate, a metabolic endprod-
uct. The most common type of PH, PH1 (MIM #259900)
is caused by a deﬁciency of the liver speciﬁc, peroxisomal,
pyridoxal phosphate-dependent enzyme alanine:glyoxylate
amino transferase (AGT; EC 2.6.1.44) [1, 2]. The second
type, PH2 (MIM #260000), is caused by a deﬁciency in
glyoxylate reductase/hydroxypyruvate reductase (GRHPR;
EC 1.1.1.26/79) [3–5], a cytosolic enzyme. The recently
identiﬁed PH type 3 (MIM #613616) [6]i sl i n k e dt ot h e
gene DHDPSL, encoding a mitochondrial enzyme, although2 International Journal of Nephrology
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Figure 1: Reactions involved in oxalate,glyoxylate, and glycolate metabolism in human hepatocytes. Abbreviations:AGT alanine:glyoxylate
aminotransferase;GR/HPR glyoxylate reductase/hydroxypyruvate reductase; GO glycolate oxydase; LDH lactate dehydrogenase.
the metabolic reactions involved remain to be conﬁrmed.
All three are autosomal recessive diseases. AGT catalyses the
transamination ofglyoxylatetoglycinewhilepyruvateiscon-
verted to alanine, whereas GRHPR catalyses the reduction of
glyoxylate to glycolate [7]. The failure to detoxify glyoxylate
inPH1and2resultsinitsconversionintooxalatebycytosolic
l a c t a t ed e h y d r o g e n a s e .S i n c et h em a i ns o u r c eo fo x a l a t e
removal from the body is urine excretion, the deposition
of the calcium oxalate salt, which is very poorly soluble,
occursprimarily there eitheras urolithiasis along the urinary
tract or in the kidney, or as interstitial deposition in the
kidney leading to nephrocalcinosis [8]. The accompanying
overproductionofglycolatein PH1orL-glycerateinPH2has
no identiﬁed consequence. The crystal structures for both
AGTandGRHPRhavebeensolved,andsomerationalization
oftheeﬀectofmutationsin theAGXT and GRHPRgeneshas
been possible [9, 10].
3.Epidemiology
PH are rare autosomal-recessive inherited disorders. PH1 is
the most common form of PH. The disease has an estimated
prevalence ranging from 1 to 3 per million population and
an estimated incidence rate of ∼1:100,000 live births per
year in Europe [11–13]. Higher rates are reported from
inbred populations [14]. PH accounts for <1% of pediatric
ESRD population in registries from USA, UK, and Japan
[15–17]. In contrast, PH is more prevalent in countries
where consanguineous marriages are common. Due to lack
of registries, epidemiological information from developing
countries primarily originates from major referral centers.
Approximately10%ofKuwaitichildren and 13%ofTunisian
children with ESRD have been reported to have PH [18, 19].
Incidence and prevalence of other types of PH are unknown
but appear to be much lower than PH1.
4.ClinicalFeaturesand OxalateBurden
Owing to the high urinary oxalate excretion, the urine
become supersaturated for calcium oxalate (CaOx) resulting
in the formation of crystals within the tubular lumen.
PH1, therefore, manifests as severe urolithiasis and/or
nephrocalcinosis (Figure 2). Progressive renal parenchyma
inﬂammation andinterstitialﬁbrosisduetonephrocalcinosis
and recurrent urolithiasis cause renal impairment, which
usually progresses to ESRDover time [8]. Once the GFR falls
below 30–50mL/min per 1.73m2, reduced renal excretion
of oxalate by the kidneys together with continued over-
production by the liver lead to an increase plasma oxalate
(Pox) that exceeds the supersaturation point for CaOx (Pox
>30µmol/l). Systemic deposition of CaOx, namely, oxalosis,
canthenoccurinmany organs suchas bone,retina, skin, soft
tissues, heart, vessels, and central nervous system (Figure 3).
Severe systemic complications result in high morbidity and
poor quality of life and, if treated late or untreated, early
d e a t h .T h eb o n ec o m p a r t m e n ts e e m st ob et h em a i ns i t e
for oxalate storage (15 to 910 in PH1 patients versus 2
to 9µmol of oxalate per gram of bone tissue in non-PH1
ESRD patients) [20]. The skeleton can therefore store huge
amounts of oxalate, even though the threshold of GFR at
which this occurs is debated. Clinically, PH1 patients can
experience severe bone pains and pathological fractures with
low-trauma mechanism, as well as EPO-resistant anemia.
Jointscanalsobedamaged,withsynovitis, chondrocalcinosis
and oxalate deposits. Characteristics of oxalate osteopathy
on X-ray include dense metaphyseal bands, submarginalInternational Journal of Nephrology 3
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Figure 2: Abdomen X-ray (a) and renal ultrasonography (b) showingurolithiasis and nephrocalcinosis in PH1.
metaphyseal lucency, sclerosis of adjacent diaphysis, cystic
bone changes, deformities, subperiosteal resorption, blurred
trabecular pattern, radio-opaque rims in ﬂat bones and
epiphyseal nuclei, as well as increased bone density in
vertebra and iliac crest [21, 22]. Symmetrical transverse
lines of increased bone density at areas of rapid growth
have been related to crystalline precipitation in cartilage
calciﬁcationsitesaswellasinhematopoieticandotherhighly
vascularized areas [23, 24]. Bone biopsies from the iliac crest
can show speciﬁc features: oxalate crystals often surrounded
by a granulomatous reaction corresponding to an invasion
of bone surface by macrophages [20]. Instead of invasive
bone biopsy, bone mineral density (BMD) measurement
could be a valuable and noninvasive tool in determining
and monitoring oxalate burden in PH1 [25]. Using a new
bone imaging technique (e.g., high-resolution peripheral
quantitative computed tomography, HR-pQCT), it has been
shown thatchildren with PH1had decreased compartmental
volumetric BMD and bone modiﬁcations with disorganized
trabecular microarchitecture [26].
5.Diagnosis
5.1. PH1. The median age at initial symptoms of PH1 is 4
to 7 years in Europe and 13 years in Japan, ranging from
birth to the sixth decade [13, 27, 28]. PH1 has variable
presentation. The infantile form often presents as a life-
threatening condition because of rapid progression to ESRD
due to both early oxalate load and immature GFR; one half
of the patients experience ESRD at the time of diagnosis
and 80% develop ESRD by the age of 3 years [29]. Other
presentations include recurrent urolithiasis and progressive
renal failure in childhood or adolescence, late-onset form
with occasional stone passage and sometimes ESRD as the
ﬁrst symptom in adulthood, diagnosis made after recurrence
posttransplantation and presymptomatic individuals with a
family history of PH1 [30]. Sonographic examination may
show either cortical or medullary nephrocalcinosis [31].
Because of the rarity of disease, physicians are likely to
encounter few or no PH patients during their practicing
lifetime. The diagnosis of PH is, therefore, often delayed for
years [12, 27, 32]. At time of diagnosis, a high proportion
of patients (10–40%) had already reached ESRD [11–13,
27, 32, 33]. Overall, ESRD is reached by the age of 24 to
33 years in half of the patients with PH1 [27, 33]. The
combination of both clinical and sonographic ﬁndings, that
is, the association of stone passage, nephrocalcinosis, and
renal impairment, is a strong argument for clinical diagnosis
of PH1. Family history may bring additional information.
Crystalluria andinfrared spectroscopy are ofmajorinter-
est foridentiﬁcation(qualitative)and quantitativeanalysis of
crystals and stones (Figure 4), showing CaOx monohydrate
crystals (type Ic whewellite) [34]. In patients with normal or
signiﬁcant residual GFR, concomitant hyperoxaluria (urine
oxalate >1mmol/1.73m2 per day, reference value <0.5)
and hyperglycoluria (urine glycolate >0.5mmol/1.73m2,
reference value<0.5)areindicativeofPH1,butsomepatients
do not present with hyperglycoluria. The measurement of
oxalate in a timed 24-hour urine collection corrected for
body surface area is preferred for the diagnosis of PH [35].
Random urine oxalate/creatinine ratios can be useful to
estimate oxalate excretion, particularly in infants, or patients
with inability to provide complete 24-hour collection [36,
37]. Reference age-related values for oxalate and glycolate
excretion have been established (Table 1). Urinary oxalate
excretion may be falsely low in patients with decreased
GFR because of oxalate retention and systemic deposition as
calcium oxalate. In PH patients with GFR <30mL/min per
1.73m2, Pox is usually >20–30 µmol/L, and in those with
ESRD, Pox is >50µmol/L. In ESRD patients, plasma oxalate
(± glycolate)/creatinine ratio and oxalate (± glycolate)
measurement in dialysate might also be helpful for screening
[38].
Until recently, liver biopsy to measure AGT catalytic
activity has been essential for deﬁnitive diagnosis of PH1.
As an alternative approach, genetic analysis of AGXT gene
allows to detect mutations in most of suspected patients,
thereby, supplanting the need for liver biopsy as a ﬁrst4 International Journal of Nephrology
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Figure 3: Systemic involvement (“oxalosis”) in PH1. Calcium oxalate deposition in the bones and joints (a), the vessels (b), and the retina
(c).
(a) (b)
Figure 4: Calcium oxalate stones (a) and urine microscopic examination showingcalcium oxalate monohydrate crystals (b) in PH1.
step [39] .I nt h ep r e s e n c eo fa t y p i c a lp r e s e n t a t i o no ri n
patients with no mutation identiﬁed, however, a deﬁnitive
diagnosis requires AGT activity measurement in liver tissue.
The AGXT gene is located on chromosome 2 (2p37.3).
It is noteworthy that among more than 150 mutations
responsible for PH1 found throughout the 11 exons of the
AGXT gene [40], many, corresponding to almost 50% of
the patients, cosegregate with a so-called minor allele, the
most prominent feature of which is a proline to leucine
change in position 11 [41]. The frequency of this minor
allele is highest in the Caucasian population, and it acts
in synergy with some of the mutations, in particular, the
common p.Gly170Arg change [41, 42]. If most of the
mutations in PH1 are “private” mutations, some mutations
occur more commonly [39]. The most frequent mutation,
p.Gly170Arg, is found in 20 to 40% of patients and is
associated with signiﬁcant residual catalytic AGT activity
in liver biopsies [43]. Some mutations are found among
speciﬁc ethnic groups, the most obvious example being the
p.Ile244Thr mutation which is found in many patients of
North African/Spanish origin [44]. Prenatal diagnosis can
be performed from DNA obtained from crude chorionic
villi or amniocytes, on the basis of a restricted analysis of
exons including mutation(s) identiﬁed in the index case.
Such a procedure allows the identiﬁcation of fetuses aﬀected
or not with PH1. Independently of the diagnostic value,International Journal of Nephrology 5
Table 1: Reference age-related values for urinary oxalate, glycolate,
and L-glycerate excretion (adapted from [8]).
Units Normal values
Oxalate Glycolate L-Glycerate
mmol/1.73m2 per day <0.5 <0.5
µmol/l <5
mmol/molcreatinine
0–6 months <325–360 <363–425 14–205
7–24 months <132–174 <245–293 14–205
2–5 years <98–101 <191–229 14–205
5–14 years <70–82 <166–186 23–138
>16 years <40 <99–125 <138
mutation analysis may bring information on pyridoxine
responsiveness, on complex enzyme phenotype, and some-
times on clinical prognosis [27, 40]. Although PH1 usually
shows marked inter- and intrafamilial heterogeneity [45–
47], genotype-phenotype correlations have been described
for some mutations [27, 48].
5.2. Other Types of PH. Symptoms onset in PH2 typically
occurs in childhood. Although patients with PH2 are also at
risk for ESRD and systemic oxalosis, they appear to form less
stones, have a less pronounced nephrocalcinosis, and a lower
incidence of ESRD over time than PH1 patients [49, 50].
In the presence of hyperoxaluria without hyperglycoluria,
a diagnosis of PH2 should be considered, especially when
AGT activity is normal. The diagnosis is based on increased
urinary excretion of L-glycerate (reference values in Table 1),
but the deﬁnitive diagnosis may require the measurement
of GRHPR activity in a liver biopsy [51, 52]a ss o m eP H 2
patients have normal level of L-glycerate in urine [53].
Genotyping can provide reliable diagnosis for PH2. The
GRPHR gene is located on chromosome 9 (9q11) [5]a n d
more than 15 mutations have been identiﬁed so far.
A few patients referred to as non-1 non-2 PH have been
described. These patients have a phenotype similar to PH1
or 2 butno AGT or GRHPR deﬁciency. Recently,a third type
of PH, PH3, caused by mutations in the gene DHDPSL has
been characterized among non-1 non-2 PH patients [6].
In this paper, we propose an algorithm for the diagnosis
and the conservative treatment of PH as illustrated in the
Figure 5.
6.Treatment
6.1. Conservative Measures. Conservative measures should
be initiated as soon as basal urinary oxalate measures
have been completed and while renal function persists.
Once ESRD has been reached, pyridoxine is the only stone
treatmentthatshouldbepursued,ifthepatientisresponsive.
These measures apply to all types of PH with the exception
of pyridoxine which is speciﬁc to some PH1 patients.
6.1.1. High Fluid Intake. The positive eﬀect of high ﬂuid
intake has been proven in epidemiological and prospective
intervention studies in stone formers [54]. In PH, the ﬂuid
intake recommended is >2L/m 2 per day (up to 3L/m2 per
day), distributed throughout the day and night. In small
children and infants, a feeding or gastrostomy tube may
be required. Special care should be taken in situations of
ﬂuid losses (diarrhea, vomiting, and fever) or limited oral
hydration (surgery) and intravenous ﬂuid intake instituted
if necessary.
6.1.2. Diet. Oral calcium can bind oxalate in the bowels, and
calciumrestriction hasbeenshowntoresultinhigheroxalate
intestinal absorption [55, 56]. Calcium intake should thus
remain normal. A restriction in oxalate intake is of limited
usefulness in PH patients as the main source of oxalate is
endogenous.Excessiveintakeof vitamin Cand vitamin D are
to be avoided.
6.1.3. Inhibition of Calcium Oxalate Crystallization. Alkali
citrate can reduce the urinary calcium oxalate saturation
by forming complexes with calcium thus decreasing stone
growth or nephrocalcinosis [57]. Potassium, or sodium,
citrate at a dose of 100–150mg/kg body weight per day (0.3–
0.5mmol/kg) is recommended. Pyrophosphate ions may
decrease calciumoxalate crystallization although orthophos-
phate has never been evaluated in isolation of other treat-
ments [58]. Moderate doses of elemental phosphorus 20–
30mg/kg body weight per day may be administered. There
i sa sy e tn oe v i d e n c et h a tp r o b i o t i c s ,s u c ha sOxalobacter
formigenes despite its ability to metabolize oxalate [59],
can signiﬁcantly decrease urinary oxalate excretion in PH
patients.
6.1.4. Pyridoxine. The cofactor of AGT is pyridoxal phos-
phate, one of the B6 vitamins. The administration of
pyridoxine hydrochloride has been shown to be associated
with a decrease in urinary oxalate in about 10–30% of
patients with PH [60, 61]. The metabolic basis of pyri-
doxine responsiveness is unclear. All PH1 patients should
be tested for pyridoxine responsiveness and treated until
liver transplantation is performed, if responsive, even while
undergoing hemodialysis. Studies have determined that a
subset of patients with PH1, carrying 1 or 2 copies of AGT
mutations (p.Gly170Arg or p.Phe152Ile), may be responsive
to pharmacological doses of pyridoxine, though this list is
not limitative [48, 62]. Responsiveness has been deﬁned
as a minimum 30% decrease in urinary oxalate excretion
after a test period of a minimum 3 months at maximum
dose [61]. The starting dose recommended is 5mg/kg per
day and can be increased to 10mg/kg per day. No sensory
neurotoxicity has been described in PH patients, and a
dose of 500mg per day is thought to be below toxic levels.
Absorption of pyridoxine may vary between patients, and
assessing plasma levelsofpyridoxal phosphatemay beuseful,
though therapeutic levels are not deﬁned.
Added monitoring of the tolerance and eﬃcacy of these
measures may require evaluation of stone formation, and
nephrocalcinosis by ultrasounds or X-ray, urinary pH and
volume, urinary citrate, magnesium and oxalate excretion6 International Journal of Nephrology
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Figure 5: Proposed algorithm for the diagnosis and conservative treatment of primary hyperoxalurias. Abbreviations: PH: primary
hyperoxaluria; GFR: glomerular ﬁltration rate; Uox: urinary oxalate; Pox: plasma oxalate; CaOx: calcium oxalate; AGT: alanine:glyoxylate
amino transferase; AGXT: AGT gene; GR/HPR: glyoxylate reductase/hydroxypyruvate reductase.
and supersaturation, and crystalline volume in the urines. In
summary, an aggressive supportive management should be
started assoon asthediagnosisofPHhasbeensuspected and
may improve renal survival provided compliance is optimal
[63].
6.2. Urology. The treatment of stones should avoid open and
percutaneous surgery because further renal lesions will alter
GFR. The use of extracorporeal shock wave lithotripsy may
be an available option in selected patients, but the presence
of nephrocalcinosis may be responsible for parenchymalInternational Journal of Nephrology 7
Table 2: Suggestions for organ transplantation strategies in PH1 patients according to residual GFR (ml/minper1.73m2), systemic
involvement, and local facilities (from [68]).
Tx strategy Combined simultaneous
liver + kidney
Liver ﬁrst Kidney as a
second step Isolated kidney Isolated liver
HD strategy
Peroperative ±
postoperative according
to Pox and GFR
Standard HD following
liver Tx aiming at Pox
<20µmol/L
Pre- and peroperative Sometimes peroperative
40 < GFR < 60 No No No Optional
20 < GFR < 40 Yes No
(1) In developing
countries
(2) In very selected
patients
No
GFR < 20 Yes Yes No No
Infantile form
(ESRD <2y e a r s ) Yes Yes (emergency) No No
Abbreviations: ESRD end-stage renal disease; GFR glomerular ﬁltration rate; HD hemodialysis;Pox plasma oxalate; Tx transplantation.
damage. In patients with repeated renal colic, a ureteral JJ
stent may be helpful for pain control and protection of renal
damage. Bilateral nephrectomy may be proposed in patients
on renal replacement therapy in order to limit the risk of
infection, obstruction, and passage of stones.
6.3.Dialysis. Conventional dialysis is inadequatefor patients
who have reached ESRD, because it cannot overcome the
ongoing oxalate production [64]. This results in continuing
tissue deposition of oxalate and risk of organ damage. The
removalofoxalatebyhemodialysisexceedsthatbyperitoneal
dialysis [65]. Better results may be obtained by combining
daily high-ﬂux hemodialysis and peritoneal dialysis or by
long daily hemodialysis sessions [66, 67].
In summary, there are limited indications for dialysis
in patients with PH1 [30]: (1) if diagnosis of PH1 has not
been established, (2) in small children with infantile oxalosis
waitingfororgan Tx,(3)in preparationforkidneyTx,before
orafterliverTx,inordertodepleteoxalatefromthebody,(4)
following isolated kidney or combined liver-kidney Tx with
anydelayinachieving optimalrenalfunction, asa temporary
adjunct in the case of high oxalate burden, or with transient
loss of transplant function, (5) very exceptionally in older
patientsiftheonlyalternativeisno dialysis,(6)indeveloping
countries; hemodialysis (or even less satisfactory, peritoneal
dialysis) may be indicated as only a preference to absolute
withdrawal of all therapy.
7.OrganTransplantation
Ideally, organ transplantation should be planned prior to
the onset of ESRD and systemic oxalosis. The diﬀerent
options for organ Tx for PH1 according to residual GFR are
summarized in Table 2 [68].
7.1. Kidney Transplantation. Kidney Tx allows signiﬁcant
removal of soluble Pox [69]. However, because the biochem-
ical defect is in the liver, overproduction of oxalate and
subsequent deposition in tissues continues unabated. The
high rate of urinary oxalate excretion originates from both
ongoing oxalate production from the native liver and oxalate
deposits in tissues leading to high risk for disease recurrence.
Isolated kidney Tx for PH1 is no longer recommended,
because frequent recurrence leads to poor graft survival and
patient quality of life. In Europe, the European Dialysis
Transplantation Association (EDTA) registry reported poor
results of isolated kidney Tx two decades ago with a 3-
year graft survival of 17 to 23% according to donor source
[70]. A United States Renal Data System (USRDS) analysis
of 190 adults transplanted in the US between 1988 and
1998 showed superior death-censored kidney graft survival
in combined liver-kidney Tx than in isolated kidney Tx, but
no diﬀerence in patient survival [71]. More recently, data
from 58 PH1 patients showed a death-censored kidney graft
survival at 3 years of 95% with combined liver-kidney Tx
versus 56% with isolated kidney Tx [72]. Proven pyridoxine
responsive patients may beneﬁt from isolated kidney Tx,
provided pyridoxine is maintained, but the clinical evidence
forthis isstill sparse. IsolatedkidneyTxmay bealso regarded
as a temporary solution in some developing countries before
managing the patient in a specialized center for further
combined liver-kidney procedure.
Isolated kidney Tx might be the treatment of choice in
patients with PH2. Indeed, PH2 patients with kidney Tx
alone appear to have a more favorable course than PH1
patients, and the beneﬁt of liver Tx in such patients is still
unclear.
7.2. Liver Transplantation. Since the liver is the only organ
responsible for glyoxylate detoxiﬁcation by AGT, the exces-
sive production of oxalate will continue as long as the native
liver is left in place. Therefore, PH1 can be cured only when
the deﬁcient host liver has been removed. Liver Tx is a
form of gene therapy as well as enzyme replacement therapy
as it will supply the missing enzyme in the correct organ
(liver), cell (hepatocyte), and intracellular compartment
(peroxisome).
In Europe, combined liver-kidney Tx has been the
preferred approach in the past 25 years. A European PH18 International Journal of Nephrology
Transplant registry reported 127 liver Tx including more
than 100 liver-kidney Tx in 117 patients between 1984 and
2004 [73]. Results were encouraging with patient survival
rates of 86, 80, and 69% at 1 year, 5 years, and 10 years,
respectively. There were 13 kidney graft failures. Comparable
results have been reported from the USRDS, with a patient
survival above 80% at 5 years and a death-censored graft
survival of76%at8years post Tx[71].Suchastrategy can be
successfully proposed to infants with PH1 [74]. Worldwide
experience indicates that once perioperative mortality is
avoided,combined liver-kidney Tx seems to be an acceptable
treatment for PH1 [75–77]. The strategy of combined liver-
kidney Tx may be inﬂuenced by the stage of the disease
(Table 2). Simultaneous liver and kidney Tx is logical in
patients with a GFR between 15 and 40mL/min per 1.73m2,
because, at this level, oxalate retention increases rapidly.
A sequential procedure (ﬁrst liver Tx, then dialysis until
suﬃcient oxalate has been cleared from the body, followed
by kidney Tx) may be proposed to ESRD patients, mainly
infants with a long waiting time [78].
Preemptive isolated liver Tx might be the ﬁrst option
in selected patients before advanced chronic renal fail-ure
has occurred, that is, at a GFR between 60 and 40mL/min/
1.73m2. In the Hamburg experience, 4 pediatric recipients
with a GFR between 27 and 98mL/min per 1.73m2 received
a preemptive liver transplant, and 3 of them still have
signiﬁcant residual renal function after a median followup
of ∼12 years [79]. Another group reported good results at 5
years in 4 PH1 children who received a preemptive liver Tx
with a mean pretransplant GFR of 81mL/min/1.73m2 [80].
Such a strategy has a strong rationale but raises ethical con-
troversies especially when the GFR is superior to 60mL/min
per1.73m2. Indeed PH1 is the only peroxisomal disease
without psychomotor delay due to cerebral involvement,
and the conservative management of PH1 patients has
signiﬁcantly improved during the last 10 years; this may
inﬂuence the role of preemptive liver Tx in such patients.
The choice of donor source may be based either on
immunological bases (i.e., using the same donor for both
organs) or on biochemical rationale (i.e., using a two-step
procedure according to oxalate body store). Indeed most
publication currently report on the use of cadaver donors
but a living related donor may be considered under certain
conditions [78].
7.3. Posttransplantation Reversal of Renal and Extrarenal
Involvement. After combined liver-kidney Tx, urinary gly-
colate immediately returns to normal and Pox returns to
normal before urine oxalate does [81]. Indeed, urinary
oxalate can remain elevated for as long as several years
post-Tx, due to the slow resolubilization of systemic CaOx
deposition [72]. Therefore, recurrent nephrocalcinosis or
renal calculi are still a risk and may jeopardize graft function.
Thus, independent of the Tx strategy, the kidney must be
protected against the damage that can be induced by heavy
oxalate load suddenly released from tissues. Forced ﬂuid
intake (3–5Lper1.73m2 per day) supported by the use of
crystallization inhibitors is the most important approach.
Pox, crystalluria, and CaOx saturation are helpful tools
in renal management after combined liver-kidney Tx. The
beneﬁt of daily high-eﬃciency post-transplant hemodialysis
is still debated and should be limited to patients with
signiﬁcant systemic involvement (Table 2). It will provide a
rapid drop in Pox and, therefore, reduce the exposure of the
transplanted organs to high Pox, but it may also increase
the risk of CaOx supersaturation due to reduction in urine
volume in the case of inappropriate ﬂuid removal. However,
posttransplant hemodialysis is mandatory in patients with
acute tubular necrosis or delayed graft function.
8.ConclusionandFutureProspects
Patients with hyperoxaluria should be referred for diagnosis
and management to reference centers with interest and
experience in the conditions and access to the appropri-
ate biochemical and molecular biological facilities. Major
advances in biochemistry, enzymology, genetics, and man-
agement have been achieved during recent years. Improved
knowledgeofthedisease,earlyandaccuratediagnosis,before
renal failure occurs, and aggressive supportive treatment
are of critical importance for the prognosis. In (pre)ESRD
patients, the greatest experience has been obtained with one-
step combined liver-kidney transplantation. New insights
into potential therapiesincluding the restoration of defective
enzymatic activity through the use of chemical chaperones
and hepatocyte cell transplantation, or recombinant gene
therapy for enzyme replacement [82–84], provide hope for
curative treatments of primary hyperoxalurias in the future.
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